These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 27627582)

  • 1. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
    Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
    J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    Chen Y; Wei J; Cai J; Liu A
    BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
    Gerber NK; Yamada Y; Rimner A; Shi W; Riely GJ; Beal K; Yu HA; Chan TA; Zhang Z; Wu AJ
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):322-9. PubMed ID: 24679729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
    Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
    Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
    Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
    PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
    Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
    Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
    Iuchi T; Shingyoji M; Sakaida T; Hatano K; Nagano O; Itakura M; Kageyama H; Yokoi S; Hasegawa Y; Kawasaki K; Iizasa T
    Lung Cancer; 2013 Nov; 82(2):282-7. PubMed ID: 24021541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).
    Zhu Q; Sun Y; Cui Y; Ye K; Yang C; Yang D; Ma J; Liu X; Yu J; Ge H
    Oncotarget; 2017 Feb; 8(8):13304-13311. PubMed ID: 28076323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
    Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
    Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases.
    Lee HH; Chen CH; Chuang HY; Huang YW; Huang MY
    Sci Rep; 2019 Nov; 9(1):16834. PubMed ID: 31728013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
    Chen L; Fu M; Zhou J; Yao Y; Zhou J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
    Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.